Welcome to our dedicated page for Lite Strategy SEC filings (Ticker: LITS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lite Strategy, Inc. filings document the company’s public-company transition, operating results, Litecoin treasury strategy, and capital-allocation actions. Form 8-K disclosures include furnished financial results, the board-authorized common stock repurchase program, and equity securities activity tied to pre-funded warrants issued in a private placement.
The filings also cover governance and compensation matters, including annual meeting voting results, director elections and resignation, executive appointment to chief executive officer and the board, stock option grants, and approval of the 2026 Omnibus Equity Compensation Plan. SEC reports identify MEI Pharma, Inc. as the company’s former name and support the current Lite Strategy identity.
Lite Strategy, Inc. filed an amended report to correct the previously disclosed size of stock options granted to its Chief Executive Officer, Justin J. File. The original filing stated that Mr. File received options to purchase 635,000 shares of common stock, but the actual grant on November 14, 2025 was for options on 180,000 shares under the company’s existing equity plan.
To address this discrepancy, on November 20, 2025 the board approved additional “Replacement Options” for Mr. File to purchase 455,000 shares of common stock. These replacement options carry an exercise price of $2.02 per share and follow the same vesting terms as the original 180,000-share grant. The replacement options will only be issued if stockholders approve a new omnibus equity plan at the company’s 2026 annual meeting; they will be cancelled if that plan is not approved.
Lite Strategy, Inc. (LITS) reported an insider stock purchase by a company director. On 11/19/2025, the director bought 12,100 shares of Lite Strategy common stock in an open-market transaction coded "P" for purchase. The weighted-average purchase price was $1.8824 per share, with individual trades executed between $1.87 and $1.90 per share.
Following this transaction, the director beneficially owns 30,000 shares of Lite Strategy common stock in direct ownership. The filing notes that detailed trade-by-trade pricing information within the stated range is available upon request from the company, its security holders, or the SEC staff.
Lite Strategy, Inc. (LITS) reported a Form 4 showing that director Nicholas Glover received a customary annual grant of stock options. On 11/14/2025, he was granted options to purchase 55,000 shares of Lite Strategy common stock at an exercise price of $2.02 per share, expiring on 11/14/2035. These options are held as direct ownership.
The options vest over time as board compensation. 16.66666% of the grant vested on the grant date, with the remaining options vesting in equal monthly installments beginning 12/14/2025 and continuing on the first day of each month through 11/14/2026. The filing states the grant was received as compensation for service on the company’s Board of Directors.
Lite Strategy, Inc. (LITS) reported an equity award to one of its directors in the form of stock options. On 11/14/2025, the director received an option grant covering 55,000 shares of common stock at an exercise price of $2.02 per share. These options are a customary annual grant to non-employee directors and were received as compensation for board service. The options vest over time, with 16.66666% vesting on the grant date and the remaining portion vesting in equal monthly amounts beginning 12/14/2025 and continuing through 11/14/2026, encouraging ongoing alignment between the director’s interests and those of shareholders.
Lite Strategy, Inc. (LITS) reported that a non-employee director received stock option awards. On November 14, 2025, the director was granted a stock option to purchase 55,000 shares of common stock at an exercise price of $2.02 per share, exercisable through November 14, 2035. This grant is described as a customary annual award to non-employee directors and vests 16.66666% on the grant date, with the remainder vesting monthly from December 14, 2025 through November 14, 2026.
On the same date, the director also received a separate stock option for 10,000 shares of common stock at an exercise price of $2.02 per share, also expiring on November 14, 2035. This option is described as a customary grant upon appointment to the Board, as revised on November 14, 2025, and vests in 36 equal monthly installments beginning one month after the grant date, subject to continued service.
Lite Strategy, Inc. (LITS) reported that a non-employee director received a customary annual stock option grant. On 11/14/2025, the director was awarded options to purchase 55,000 shares of common stock at an exercise price of $2.02 per share as compensation for board service. The options vest over one year, with 16.66666% vesting on the grant date and the remaining options vesting in equal monthly amounts beginning 12/14/2025 and continuing through 11/14/2026. The options expire on 11/14/2035 and are held directly by the reporting person.
Lite Strategy, Inc. reported an insider equity award for its chief executive. A Form 4 shows that the CEO, CFO, Secretary and director received a stock option to buy 635,000 shares of common stock at an exercise price of $2.02 per share on 11/14/2025 as employment compensation. The option is scheduled to vest in 36 equal monthly installments, with the first installment vesting one month after the grant date, subject to continued service through each vesting date.
Lite Strategy, Inc. announced that its Board has appointed Justin J. File as permanent Chief Executive Officer and elected him to the Board of Directors, effective immediately. He will continue to serve as Chief Financial Officer and Secretary, consolidating the company’s top executive and financial roles under a single leader.
In connection with his promotion, Mr. File received stock options to purchase 635,000 shares of common stock at an exercise price of $2.02 per share, which was the closing price on the grant date. These options were issued under the company’s Amended and Restated 2008 Stock Omnibus Equity Compensation Plan and vest in 36 monthly installments starting December 14, 2025, with a 10-year term. Mr. File will not receive additional compensation for serving on the Board, and the company plans to enter into an addendum to his employment agreement to document the new terms.
Lite Strategy, Inc. (Nasdaq: LITS) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $3.6 million, a narrower loss than the $8.0 million in the prior year period, as operating expenses declined with R&D falling to $10 thousand and G&A to $3.1 million. A $0.6 million loss from change in fair value of digital assets was recognized.
Balance sheet strength shifted to digital assets. Cash and cash equivalents were $10.1 million, and Litecoin holdings were $99.4 million, reflecting 929,548 LTC acquired under the new Litecoin Treasury Strategy following a $100.0 million July 2025 PIPE. Total assets were $113.3 million and stockholders’ equity was $112.3 million.
Capital actions and liquidity. In July, the company issued 23.2 million common shares at $3.42 and pre-funded warrants in the PIPE, and raised an additional $4.6 million net via its ATM. Operating cash use was $4.5 million; $100.0 million was deployed to purchase LTC; financing provided $96.6 million. Subsequent to quarter-end, remaining PIPE pre-funded warrants were exercised and the Board authorized a $25.0 million share repurchase program.
Lite Strategy, Inc. (LITS) filed an 8-K announcing two items. First, Thomas C. Reynolds, M.D., Ph.D. notified the Board on October 24, 2025 of his decision to resign as a director, effective November 4, 2025. He will also step down from the Compensation Committee and the Nominating & Governance Committee. The company stated his resignation is not the result of any disagreement with operations, policies, or practices.
Second, the Board authorized a common stock repurchase program under which the company may purchase up to $25 million of its common stock, as announced via press release on October 29, 2025. Repurchases may occur in the open market, through privately negotiated transactions, or under Rule 10b5-1 plans, subject to market conditions, applicable law, and other factors. The program does not obligate any repurchases and may be suspended or discontinued at any time.